1401065-46-0

Basic information

• Product Name: (S)-4-benzyl-3-(5,5,5-trifluoropentanoyl)oxazolidin-2-one
• Synonyms: (S)-4-benzyl-3-(5,5,5-trifluoropentanoyl)oxazolidin-2-one;(4S)-4-Benzyl-3-(5,5,5-trifluoropentanoyl)-1,3-oxazolidin-2-one
• CAS NO: 1401065-46-0
• Molecular Formula: C₁₅H₁₆F₃NO₃
• Molecular Weight: 315.2876496
• Mol File: 1401065-46-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 411.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.298±0.06 g/cm3(Predicted)
• PKA: -2.33±0.40(Predicted)
• CAS DataBase Reference: (S)-4-benzyl-3-(5,5,5-trifluoropentanoyl)oxazolidin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-benzyl-3-(5,5,5-trifluoropentanoyl)oxazolidin-2-one(1401065-46-0)
• EPA Substance Registry System: (S)-4-benzyl-3-(5,5,5-trifluoropentanoyl)oxazolidin-2-one(1401065-46-0)

Safety Data

• Hazardous Substances Data: 1401065-46-0(Hazardous Substances Data)

Usage

General Description

(S)-4-benzyl-3-(5,5,5-trifluoropentanoyl)oxazolidin-2-one is a chemical compound with a unique structure that includes a benzyl group and a trifluoropentanoyl group bound to an oxazolidin-2-one ring. (S)-4-benzyl-3-(5,5,5-trifluoropentanoyl)oxazolidin-2-one is a chiral molecule, meaning it has a non-superimposable mirror image, and is commonly used in organic chemistry as a building block for the synthesis of various pharmaceuticals and agrochemicals. The presence of the trifluoropentanoyl group gives the compound unique properties, such as increased hydrophobicity and potential for use as a bioactive molecule. Due to its versatile structure and potential applications, (S)-4-benzyl-3-(5,5,5-trifluoropentanoyl)oxazolidin-2-one is a valuable compound in chemical and pharmaceutical research.

Upstream product

• 1584714-88-4 N-(6-benzoyl-2,3-dichlorophenyl)pivalamide 
• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 407-62-5 5,5,5-trifluoropentanoic acid 
• 1186202-35-6 5,5,5-trifluoro-n-valeryl chloride 

Downstream Products

• 1584647-27-7 (2R,3S)-N-((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide 
• 1584648-36-1 (2S,3R)-tert-butyl 6,6,6-trifluoro-3-(((S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoate 
• 1584648-37-2 (2S,3R)-6,6,6-trifluoro-3-(((S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoic acid 
• 1584647-28-8 (2R,3S)-N-((3S)-5-(3-chlorophenyl)-9-ethyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)-2,3-bis(3,3,3-trifluoropropyl)succinamide 
• 1584648-38-3 (2S,3R)-tert-butyl 3-((5-(3-chlorophenyl)-9-ethyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoate 
• 1584647-29-9 (2S,3R)-3-((5-(3-chlorophenyl)-9-ethyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoic acid 
• 1584648-45-2 (2S,3R)-tert-butyl 6,6,6-trifluoro-3-((5-(3-fluorophenyl)-9-(hydroxymethyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoate 
• 1584648-46-3 (2S,3R)-6,6,6-trifluoro-3-((5-(3-fluorophenyl)-9-(hydroxymethyl)-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoic acid 
• 1584648-52-1 (S)-((S)-3-((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanamido)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)methyl 2-((tert-butoxycarbonyl)amino)-3-methylbutanoate 
• 1584648-47-4 (R)-tert-butyl 2-((tert-butoxycarbonyl)amino)-3-(((2S,3R)-6,6,6-trifluoro-3-(((S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanamido)thio)propanoate 
• 1584647-90-4 tert-butyl S-(((2S,3R)-6,6,6-trifluoro-3-(((3S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-L-cysteinate 
• 1584648-48-5 (R)-methyl 2-((tert-butoxycarbonyl)amino)-3-(((2S,3R)-6,6,6-trifluoro-3-(((S)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)carbamoyl)-2-(3,3,3-trifluoropropyl)hexanamido)thio)propanoate 
• 1584647-92-6 ((3S)-3-(((2R,3S)-3-carbamoyl-6,6,6-trifluoro-2-(3,3,3-trifluoropropyl)hexanoyl)amino)-5-(3-fluorophenyl)-9-methyl-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-1-yl)methyl (4-(phosphonooxy)phenyl)acetate 
• 1584648-50-9 ((S,Z)-3-((R)-2-((S)-1-amino-3-trifluoro-1-oxopropan-2-yl)-5,5,5-trifluoropentanamido)-2-oxo-5-(3-fluorophenyl)-9-methyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-1-yl)methyl 2-(4-(di-tert-butoxyphosphoryloxy)phenyl)acetate 

Relevant articles and documents

Discovery of clinical candidate BMS-906024: A potent pan-notch inhibitor for the treatment of leukemia and solid tumors

Structure-activity relationships in a series of (2-oxo-1,4-benzodiazepin-3-yl)-succinamides identified highly potent inhibitors of γ-secretase mediated signaling of Notch1/2/3/4 receptors. On the basis of its robust in vivo efficacy at tolerated doses in

ALKYL, FLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS

Disclosed are compounds of Formula (I) and/or salts thereof: (I) wherein: R1 is CH2CH2CF3; R2 is CH2(cyclopropyl), CH(CH3)(cyclopropyl), or CH2CH2CH3/

FLUOROALKYL AND FLUOROCYCLOALKYL 1,4-BENZODIAZEPINONE COMPOUNDS AS NOTCH|INHIBITORS

Disclosed are compounds of Formula (I): (Formula (I)) wherein: R1 is -CH2CH2CF3; R2 is -CH2CH2CH2F, -CH2CF2CH3, -CH2CH